Survey by CVS Health® Reveals Escalating Concerns in Mental Health
CVS Health® Survey Highlights Growing Mental Health Concerns A recent survey conducted by CVS Health® (NYSE: CVS) in collaboration with Morning Consult reveals an alarming trend: concerns about mental health…
Bristol Myers Squibb Releases Latest Findings from Phase 3 CheckMate -73L Trial
Bristol Myers Squibb (NYSE: BMY) has provided an update on its Phase 3 CheckMate -73L trial, revealing that it did not achieve its primary endpoint of progression-free survival (PFS) in…
Sanofi and Novavax Forge Co-Exclusive Licensing Deal to Co-Market COVID-19 Vaccine and Innovate Flu-COVID-19 Combination Vaccines
Sanofi, in its pursuit of a robust vaccine portfolio, has forged a co-exclusive licensing agreement with Novavax, a biotech firm headquartered in Maryland, USA. The terms of this agreement encompass…
Keytruda Trial Progress for Endometrial Cancer Treatment
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, reported today that the Phase 3 KEYNOTE-B21 trial assessing KEYTRUDA, Merck’s anti-PD-1 therapy, alongside chemotherapy as…
Enhancing Knee Replacement Surgery Through Robot-Assisted Personalization
Total knee replacement surgery is a prevalent procedure, with approximately 790,000 surgeries performed annually in the U.S. This number is expected to rise due to factors like an aging population,…
Partnership Announcement: New Malaria Prevention Drug Collaboration with Nagasaki University, National Institute of Infectious Diseases, and MMV, Backed by GHIT Fund
Shionogi, in collaboration with Nagasaki University (Administrative Office: Nagasaki; President: Takeshi Nagayasu, M.D., Ph.D.), the National Institute of Infectious Diseases (Head Office: Shinjuku-ku, Tokyo; Director: Takashi Wakita), and the non-profit…
BeiGene Unveils Q1 2024 Financial Performance and Business Developments
BeiGene, a leading global oncology firm, has unveiled its first-quarter 2024 results alongside significant business updates. John V. Oyler, Co-Founder, Chairman, and CEO at BeiGene, expressed satisfaction with the robust…
Jeffrey Kindler and Alfonso Zulueta Appointed as Independent Directors to Lupin’s Board
Lupin, a leading pharmaceutical company, has recently welcomed two distinguished individuals, Mr. Jeffrey Kindler and Mr. Alfonso “Chito” Zulueta, to its Board as Independent Directors. Mr. Kindler boasts an illustrious…
CRISPR Therapeutics’ Business Update and First Quarter 2024 Financial Report
CRISPR Therapeutics (Nasdaq: CRSP), a company dedicated to pioneering gene-based medicines for severe illnesses, has unveiled its financial performance for the first quarter ending March 31, 2024. CEO and Chairman…
Revolution Medicines Unveils Q1 2024 Financial Report and Corporate Advancements Update
Revolution Medicines, Inc. (Nasdaq: RVMD), a company focused on developing targeted therapies for patients with RAS-addicted cancers, has disclosed its financial results for the quarter ending March 31, 2024, alongside…
Vertex Unveils Financial Performance for Q1 2024
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced its consolidated financial performance for the first quarter ended March 31, 2024, while reaffirming its full-year 2024 financial outlook. Reshma Kewalramani, M.D., Chief Executive…
AstraZeneca Finalizes Equity Investment Deal with Cellectis
AstraZeneca has confirmed the successful conclusion of its equity investment agreement with Cellectis, a clinical-stage biotech firm. The investment, along with a research collaboration deal unveiled in November 2023, aims…